Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03734666
Other study ID # MCC-19630
Secondary ID R34AT009689
Status Completed
Phase N/A
First received
Last updated
Start date January 14, 2019
Est. completion date November 4, 2021

Study information

Verified date June 2023
Source H. Lee Moffitt Cancer Center and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop a treatment that can effectively help people reduce their alcohol use and quit smoking.


Description:

This study evaluates a mindfulness-based treatment to concurrently target cigarette smoking and alcohol use behaviors in adults. Aim 1: Modify an existing mindfulness-based treatment to include a focus on smoking cessation and reduced alcohol use. Aim 2: Evaluate benchmarks regarding the feasibility and acceptability of Mindfulness Based Relapse Prevention -Smoking and Alcohol Use. Aim 3: Collect and examine descriptive data on proximal and distal variables associated with increased smoking abstinence and reduced drinking.


Recruitment information / eligibility

Status Completed
Enrollment 67
Est. completion date November 4, 2021
Est. primary completion date November 4, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria Aim 1: - 18 years of age or older - Currently smoking 3 or more cigarettes per day for the past year. - Carbon monoxide level >/= 8 ppm(parts per million); should carbon monoxide level yield a result less than 8 ppm, participant will be asked to submit a urine sample to determine contine levels and the result must be >/ level 3 - Participant must be motivated to quit smoking and decrease alcohol use within the next 60 days - If male, consume >/= 5 drinks and if female consume >/= 4 drinks on at least 1 occasion in the past month - Willing and able to attend the 8 weekly group sessions - Valid home address in the Tampa Bay area - Functioning telephone number - Can speak, read and write in English Inclusion Criteria Aim 2: - 18 years of age or older - Currently smoking 3 or more cigarettes per day for the past year. - Motivated to quit smoking and decrease alcohol use within the next 60 days - If male, consumes >/= 5 drinks and if female consumes >/= 4 drinks on at least 1 occasion in the past month - Willingness and ability to attend 8 weekly video group sessions - Willingness and ability to use an email account for study materials - Valid address - Functioning telephone number - Can speak, read and write in English Exclusion Criteria: - Unable to wear nicotine patch - Participants who have an active substance use disorder other than an alcohol use disorder - Participants who have an active psychotic disorder - Current use of tobacco cessation medications - Pregnant or nursing - Participants who have a household member already enrolled in the study. - In rare cases, study staff might exclude a participant for a reason not specified here

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness Based Relapse Prevention - Smoking and Alcohol
Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
Cognitive Behavioral Therapy
Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.

Locations

Country Name City State
United States H Lee Moffitt Cancer Center and Research Institute Tampa Florida

Sponsors (3)

Lead Sponsor Collaborator
H. Lee Moffitt Cancer Center and Research Institute National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Aim 2: Number of Participants Scoring >3 Number of participants scoring >3. Patient satisfaction will be determined through a score on the Client Satisfaction Questionnaire Version 8 (Attkinson & Greenfield), where participants respond to 8 items on a 4-point scale (1=very dissatisfied; 4=very satisfied). Results reported indicate clients with a patient satisfaction score over 80%. End of Treatment at 8 Weeks
Primary Aim 2: Rate of Recruitment of Eligible Participants Rate of recruitment was measured by calculating the average of eligible participants who were recruited per week 20 weeks
Primary Aim 2: Participant Retention Percentage of participants retained through follow-up End of study at Week 16 Follow-up
Primary Aim 2: Percentage of Participants That Completed Questionnaires Percentage of participants who completed questionnaires at week 16 End of study at Week 16 Follow-up
Secondary Aim 3: Percent of Smoking Abstinence End of Treatment Participants will self-report of no smoking in the last 7 days using the 7-day point prevalence. End of Treatment at 8 Weeks
Secondary Aim 3: Percent of Smoking Abstinence at 16 Week Follow-up Percent of smoking abstinence, measured by biochemical verification of abstinence via saliva continine and self-report of no smoking in the past 7 days. Participants who report abstinence will be mailed a saliva continine kit to confirm abstinence at their 16 week follow up call. At 16 week follow-up
Secondary Aim 3: Percent of Heavy Alcohol Use at End of Treatment Percent of heavy drinking days during the prior week. Heavy drinking is defined as greater or equal to 4 drinks per day for women and greater or equal to 5 drinks per day for men. End of Treatment at 8 Weeks
Secondary Aim 3: Percentage of Heavy Alcohol Use at 16 Week Follow-up Percent of heavy drinking days during the prior week. Heavy drinking is defined as greater or equal to 4 drinks per day for women and greater or equal to 5 drinks per day for men. At 16 week follow-up
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Recruiting NCT06033599 - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement Phase 3
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Completed NCT01311830 - Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons N/A
Completed NCT04566198 - Smoking in the Paris Fire Brigade and Comparison According to the Type of Service (Permanent or On-call)
Completed NCT04107779 - Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS N/A
Completed NCT05092919 - The Effect of Sweet Flavoring on the Rewarding and Reinforcing Value of Cigarillo Use Among Young Adults Early Phase 1
Terminated NCT05274217 - Journey of Transformation Curriculum for Native American Adolescents N/A
Enrolling by invitation NCT06042361 - Enhancing Equity in Smoke-free Housing N/A
Withdrawn NCT03352635 - Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking Clinical and Biomarkers Core N/A
Completed NCT03235713 - EMA for Tobacco Control Policy Research
Completed NCT03151421 - Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home N/A
Completed NCT03446170 - Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers N/A
Completed NCT04104152 - CSD190203: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting N/A
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Recruiting NCT04429568 - THC Crossover Study N/A
Completed NCT04632030 - Shrinking the Size of the Tobacco Power Wall N/A
Completed NCT04094363 - CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems N/A